GlassScriptPhysician profile
John Ryan Aldridge
NPI 1902150089
$1,813.21
in general payments reported to CMS, 2019-2025
27 companies · $154 in 2025
The $154 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $501 · 2022: $352 · 2023: $485 · 2024: $321 · 2025: $154.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $851 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $850.95 |
| Education | $108.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $460.91 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $318.95 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $158.85 | 2021-2025 | Otezla, Repatha, Krystexxa |
| Astellas Pharma US INC | $123.44 | 2021-2023 | Veozah |
| Novo Nordisk INC | $111.23 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $94.39 | 2021-2023 | Lifevest |
| Glaxosmithkline, LLC. | $49.17 | 2021-2024 | Trelegy Ellipta |
| Paratek Pharmaceuticals, INC. | $47.79 | 2023 | Nuzyra |
| Mylan Specialty L.P. | $46.66 | 2023-2024 | Yupelri |
| Alkermes, INC. | $43.28 | 2025 | Vivitrol |
| Pfizer INC. | $42.76 | 2021 | |
| Lilly USA, LLC | $42.13 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.13 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $32.10 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.18 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $19.73 | 2024 | Rexulti |
| Amarin Pharma, INC. | $19.14 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.21 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.64 | 2025 | Caplyta |
| Novartis Pharmaceuticals Corporation | $15.40 | 2022 | |
| Philips North America LLC | $15.19 | 2024 | (Cm9) Amb Mon & Diag Und |
| Biohaven Pharmaceutical Holding Company LTD. | $15.16 | 2022 | |
| Abbott Laboratories | $14.15 | 2022 | |
| Merck Sharp & Dohme LLC | $14.02 | 2021 | |
| Supernus Pharmaceuticals, INC. | $13.70 | 2021 | |
| Braeburn INC. | $13.52 | 2025 | Brixadi |
| Biohaven Pharmaceuticals, INC. | $13.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Aldridge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.